Logo wahanariau.com
  2. Boehringer ingelheim

Boehringer ingelheim

Index
Globenewswire

Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter

Senin, 20 April 2026 - 20:12:34 Wib
Globenewswire

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Kamis, 16 April 2026 - 21:35:03 Wib
Globenewswire

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Rabu, 15 April 2026 - 21:52:00 Wib
Globenewswire

Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows

Senin, 13 April 2026 - 22:26:29 Wib
Globenewswire

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Kamis, 09 April 2026 - 20:42:52 Wib
Globenewswire

Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program

Kamis, 09 April 2026 - 20:32:20 Wib
Globenewswire

Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025

Kamis, 26 Maret 2026 - 02:13:22 Wib
Globenewswire

Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice

Kamis, 19 Maret 2026 - 04:07:41 Wib
Globenewswire

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

Jumat, 27 Februari 2026 - 20:06:33 Wib
Globenewswire

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

Kamis, 26 Februari 2026 - 21:56:02 Wib
Globenewswire

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Rabu, 28 Januari 2026 - 22:20:53 Wib
Globenewswire

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Selasa, 27 Januari 2026 - 22:02:20 Wib
Globenewswire

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Rabu, 14 Januari 2026 - 05:17:38 Wib
Globenewswire

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Selasa, 13 Januari 2026 - 06:03:08 Wib
Globenewswire

JASCAYD® (nerandomilast) Receives First Regulatory Approval for Progressive Pulmonary Fibrosis in China

Kamis, 11 Desember 2025 - 00:35:41 Wib
Globenewswire

Boehringer Ingelheim announces appointment to Board of Managing Directors

Sabtu, 29 November 2025 - 02:47:07 Wib
Globenewswire

Boehringer Ingelheim Obtains two EU CVMP Positive Opinions for Avian Influenza Vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5

Jumat, 21 November 2025 - 03:27:51 Wib
Globenewswire

Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases

Rabu, 05 November 2025 - 03:00:28 Wib
Globenewswire

Boehringer Ingelheim Acquires License from Kyowa Kirin Aimed at Developing a Novel Treatment for Patients with Autoimmune Diseases

Kamis, 30 Oktober 2025 - 22:02:26 Wib
Globenewswire

JASCAYD® (nerandomilast) Approved in China for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Jumat, 24 Oktober 2025 - 01:15:45 Wib
Globenewswire

Boehringer’s Zongertinib Demonstrated a 77% Objective Response Rate in Treatment-naïve Patients with Advanced HER2 (ERBB2)-mutant NSCLC

Sabtu, 18 Oktober 2025 - 04:31:45 Wib
Globenewswire

Boehringer Ingelheim Advances Cancer Antibody-drug Conjugate Portfolio with Asset from AimedBio

Rabu, 15 Oktober 2025 - 21:23:58 Wib
Globenewswire

U.S. FDA Approves Boehringer’s JASCAYD® (nerandomilast tablets) as First New Treatment Option for Adults with IPF in Over a Decade

Jumat, 10 Oktober 2025 - 03:05:59 Wib
Globenewswire

Pooled Data Presented at ERS: Nerandomilast Monotherapy Linked to Nominally Significant Reduction in Risk of Death in IPF and PPF

Selasa, 30 September 2025 - 11:03:31 Wib
Globenewswire

Boehringer’s HERNEXEOS® Approved in China as First Oral Targeted Therapy for Previously Treated Patients with HER2-mutant Advanced NSCLC

Senin, 01 September 2025 - 22:42:33 Wib